Kalev Kask, Ph.D. , Chief Executive Officer
Kalev Kask completed his graduate degree with Prof. Tamas Bartfai at Stockholm University and post-doctoral training with Prof. Peter Seeburg at the Max-Planck Institute for Medical Research in Heidelberg. He then joined the neurogenomics company AGY Therapeutics of South San Francisco as a senior scientist, followed by research at Stanford University and advisory work with Asper Biotech and Toshiba prior to founding EGeen. Dr. Kask has authored numerous scientific publications and has patented genomics derived drug and diagnostic targets.
Elizabeth S. Song, Ph.D. , Vice President, Business Development
Elizabeth Song obtained her M.A. in Immunology from University of California, Santa Barbara and Ph.D. in Genetics from University of California, Berkeley. She completed her postdoctoral fellowship with Dr. Per A. Peterson at The Scripps Research Institute and was a recipient of the Damon Runyon Cancer Research Foundation Fellowship. Subsequently, she held positions at Chiron Corporation as Senior Scientist and at Virologix Corporation as the Director of Viral Research. Followed by her consulting roles to several Pharmaceutical and Biotechnology Companies including a genomics company, Lynx Therapeutics, Inc., she joined Lynx as the Director of Corporate Development in 2000. Subsequently, she was the Director of Business Development and Alliances Management, responsible for initiating, negotiating and managing Lynx's technology development alliances with academic and corporate partners. She was also responsible for managing technology evaluation, scientific licensing and customer support. She joined EGeen in June 2003 and is responsible for overall business development activities at EGeen.
Margus Annuk, M.D., Ph.D., Vice President, Medical Affairs
Margus Annuk received his M.D. degree from Tartu University and his Ph.D. degree from University of Uppsala with Prof. Bengt Fellstrom. His extensive research covers the area of renal diseases and transplantation, the field of cardiovascular risk factors (biomarkers), and drug effects on endothelial function, malnutrition, chronic inflammation and antioxidative status. He held a position of Associate Professor at the Tartu University and currently is an adjunct professor of medicine at Tallinn University. He joined EGeen in May 2003 as the Director of Clinical Development to spearhead the clinical development operations.
Dag Ainsoo, M.A., Director of Finance and Operations
Dag Ainsoo joined EGeen in September 2008 as a Director of Operations. Prior to that, he worked in PricewaterhouseCoopers, Silicon Valley. He received his M.A. degree in Business Administration from Tallinn Technical University, Estonia and also studied International Finance and Management Consulting in Lund University, Sweden.
